Investigation of the Prevalence of Hepatopulmonary Syndrome in Cirrhosis Patients Caused by Hepatitis B in Western China

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-07-27

Study Completion Date

2018-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

to investigate the prevalence of hepatopulmonary syndrome in cirrhosis patients caused by Hepatitis B in western China

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Hepatopulmonary Syndrome and Postoperative Complications After Liver Transplantation : A Case-control Study

NCT03092401

Hepatopulmonary Syndrome Liver Cirrhosis

UNKNOWN

Effect of Transjugular Intrahepatic Portosystemic Shunt on Oxygenation in Cirrhotic Patients With Hepatopulmonary Syndrome

NCT02148536

Hepatopulmonary Syndrome

COMPLETED

Prognosis of Patients With Acute-on-chronic Liver Failure

NCT05393453

Acute-On-Chronic Liver Failure

UNKNOWN

A Study to Predict Recompensation in Patients With Decompensated Cirrhosis Using Spleen Stiffness and Simple Blood Tests

NCT07087041

Decompensated Cirrhosis Hepatitis B Virus (HBV) Infection Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) +3 more

NOT_YET_RECRUITING

Acute-On-Chronic Liver Failure In Cirrhotic Patients

NCT04790435

Cirrhosis, Liver

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hepatopulmonary syndrome (HPS) occurs in approximately 4%-29% of cirrhotic patients and influences mortality. China has 100 million Hepatitis B virus (HBV) carriers and Chronic HBV infection is well-recognized risk factor for cirrhosis.But little is known about the prevalence of HPS in cirrhosis patients caused by HBV in western China. The aim of this study was to investigate the HPS incidence, and the signs, symptoms, arterial blood gas, and BMP9 in the serum of the patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatopulmonary Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

cirrhosis with HPS

Diagnosed as HPS

No interventions assigned to this group

cirrhosis without HPS

Not Diagnosed as HPS

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age: 18-80 years old;
2. American association of anesthesiologists(ASA) score: I-III;
3. Ability to comply with research programmes;
4. Voluntary participation in the study;
5. Has the history of HBV infection;
6. No primary cardiopulmonary disease (heart disease, emphysema, pneumonia, asthma, etc.)

Exclusion Criteria

1. Severe heart, lung, kidney disease coexisted;
2. American association of anesthesiologists(ASA) score≥IV; forced expiratory volume at one second (FEV1) or forced vital capacity (FVC) \<70%, or FEV1 / FVC \<0.70;
3. Mental state could not cooperate
4. Absence of written informed consent.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No